Geriatric Medicines Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Geriatric Medicines Market 

5.1. COVID-19 Landscape: Geriatric Medicines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Geriatric Medicines Market, By Therapeutics

8.1. Geriatric Medicines Market, by Therapeutics Type, 2023-2032

8.1.1. Analgesic

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Antihypertensive

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Statins

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Antidiabetic

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. PPI

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Anticoagulant

8.1.6.1. Market Revenue and Forecast (2020-2032)

8.1.7. Antipsychotic

8.1.7.1. Market Revenue and Forecast (2020-2032)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Geriatric Medicines Market, By Condition

9.1. Geriatric Medicines Market, by Condition, 2023-2032

9.1.1. Cardiovascular

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Arthritis

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Neurological

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Respiratory

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Osteoporosis

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Cancer

9.1.6.1. Market Revenue and Forecast (2020-2032)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Geriatric Medicines Market, By Distribution Channels

10.1. Geriatric Medicines Market, by Distribution Channels Type, 2023-2032

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Online Pharmacies

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Retail Pharmacies

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Geriatric Medicines Market, By Route of Administration

11.1. Geriatric Medicines Market, by Route of Administration Type, 2023-2032

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Parenteral

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Others

11.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Geriatric Medicines Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.1.2. Market Revenue and Forecast, by Condition (2020-2032)

12.1.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.1.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Condition (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.1.5.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Condition (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.1.6.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.2.2. Market Revenue and Forecast, by Condition (2020-2032)

12.2.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.2.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Condition (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.2.5.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Condition (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.2.6.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Condition (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.2.7.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Condition (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.2.8.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.3.2. Market Revenue and Forecast, by Condition (2020-2032)

12.3.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.3.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Condition (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.3.5.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Condition (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.3.6.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Condition (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.3.7.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Condition (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.3.8.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.4.2. Market Revenue and Forecast, by Condition (2020-2032)

12.4.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.4.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Condition (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.4.5.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Condition (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.4.6.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Condition (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.4.7.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Condition (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.4.8.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.5.2. Market Revenue and Forecast, by Condition (2020-2032)

12.5.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.5.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Condition (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.5.5.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapeutics (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Condition (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Distribution Channels Type (2020-2032)

12.5.6.4. Market Revenue and Forecast, by Route of Administration Type (2020-2032)

Chapter 13. Company Profiles

13.1. GlaxoSmithKline PLC

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Novartis AG

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Pfizer Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Sanofi S.A.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Bristol-Myers Squibb Company

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Boehringer Ingelheim GmbH

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Merck & Company Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Abbott Laboratories Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Eli Lilly & Company

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. AstraZeneca PLC

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms